文献速递乳腺癌支持与姑息治疗

T-DM1相关心脏毒性:晚期HER2阳性乳腺癌汇总分析

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.
PubMed 文献 · Eur J Cancer · 2020-01-07

该汇总分析纳入7项T-DM1试验的1961例晚期HER2阳性乳腺癌患者个体数据,评估心脏事件发生率及危险因素。总心脏事件率为3.37%(95%CI 2.6%-4.3%),年龄≥65岁和基线LVEF<55%为独立危险因素,多数心脏事件在停药后缓解。

要点

  • T-DM1相关总心脏事件率为3.37%,3/4级LVEF下降或CHF为0.71%。
  • 年龄≥65岁(OR 3.0)和基线LVEF<55%(OR 2.62)增加心脏事件风险。
  • 79%的心脏事件在停药后缓解,需关注老年患者心脏安全性。

核心结论

  • 接受T-DM1治疗的患者心脏事件发生率低。
  • 老年患者使用T-DM1时应密切监测心脏安全性。

研究设计与样本

  • 对7项T-DM1试验中1961例晚期HER2阳性乳腺癌患者个体水平数据进行汇总分析。
  • 其中1544例接受T-DM1单药,417例接受T-DM1联合帕妥珠单抗。
  • 主要终点为心脏事件发生率,采用逻辑回归评估危险因素。

主要发现

  • 3/4级充血性心力衰竭或LVEF下降发生率为0.71%。
  • 心脏缺血发生率为0.1%,心律失常发生率为0.71%。
  • 1/2级LVEF下降发生率为2.04%,总心脏事件率为3.37%(95%CI 2.6%-4.3%)。
  • 多因素分析显示年龄≥65岁(OR 3.0;95%CI 1.77-5.14;P<0.001)和基线LVEF<55%(OR 2.62;95%CI 1.29-5.32;P=0.008)为危险因素。
  • 79%的心脏事件在停药后缓解。

关键数值与推荐

  • 心脏事件分类包括:充血性心力衰竭或3/4级LVEF下降、心脏缺血、心律失常、1/2级LVEF下降。
  • 年龄≥65岁患者心脏事件风险OR为3.0(95%CI 1.77-5.14;P<0.001)。
  • 基线LVEF<55%患者心脏事件风险OR为2.62(95%CI 1.29-5.32;P=0.008)。

临床怎么用

  • 对接受T-DM1治疗的晚期HER2阳性乳腺癌患者应进行心脏功能监测。
  • 尤其对年龄≥65岁或基线LVEF<55%的患者,治疗期间需密切随访心脏安全性。
  • 发生心脏事件后停药,多数患者心脏功能可恢复。

局限性

  • 本文为汇总分析,非前瞻性随机对照研究。
  • 心脏事件的定义和报告可能在各试验间存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: T-DM1 has been approved for the treatment of HER2+ breast cancer. Cardiac dysfunction is a side effect of trastuzumab, a component of T-DM1. However, little is known about T-DM1-associated cardiotoxicity. METHODS: We have conducted a pooled analysis of T-DM1 trials in advanced HER2+ breast cancer cases to understand the incidence, clinical presentation as well as to establish possible risk factors for T-DM1-associated cardiotoxicity. The primary endpoint was the incidence of cardiac events (CEs). CEs were categorized as follows: (1) congestive heart failure (CHF) or grade 3/4 LVEF drop; (2) cardiac ischemia, (3) cardiac arrhythmia, (4) grade 1/2 LVEF drop. Secondary endpoints included CE recovery rate and impact of CEs on treatment discontinuation. Logistic regression was used to assess possible risk factors for CEs. RESULTS: Individual patient-level data from 1961 patients exposed to T-DM1 in seven trials were pooled. Of these, 1544 received T-DM1 and 417 T-DM1 + pertuzumab. CHF/LVEF drop grade 3/4 was reported in 0.71%, cardiac ischemia in 0.1%, cardiac arrhythmia in 0.71% and grade 1/2 LVEF drop in 2.04%. The total CE rate was 3.37% (95% confidence interval (CI), 2.6%-4.3%). Multivariate analysis showed patient's age ≥65 (OR 3.0; 95% CI, 1.77-5.14; P-value <0.001) and baseline LVEF<55% (OR 2.62; 95% CI, 1.29-5.32; P-value 0.008) as risk factors. CEs resolved in most (79%) patients after treatment discontinuation. CONCLUSION: The incidence of CEs in patients receiving T-DM1 was low. Older patients receiving T-DM1 should be carefully followed for cardiac safety during treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pondé N, Ameye L, Lambertini M, et al. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. Eur J Cancer. 2020. PMID: 31923729. doi:10.1016/j.ejca.2019.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。